Polaryx Therapeutics (NASDAQ:PLYX) Shares Down 16.3% - What's Next?

Key Points

• Shares fell 16.3% intraday, trading as low as $3.10 and last at $3.80 vs. a prior close of $4.54, on roughly 335,118 shares (about 81% below the ~1.75M average); the stock is below its 50‑day SMA of $5.28.
• Analyst coverage is mixed: Maxim Group initiated with a Buy and $10 target while Weiss Ratings opened with a Sell, leaving a MarketBeat consensus of Hold and a $10 consensus target.
• Polaryx is a clinical‑stage biotech focused on developing multi‑modal therapies—including small molecules and gene therapy—for rare pediatric lysosomal storage disorders.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) was down 16.3% during trading on Wednesday . The company traded as low as $3.10 and last traded at $3.80. Approximately 335,118 shares changed hands during trading, a decline of 81% from the average daily volume of 1,747,495 shares. The stock had previously closed at $4.54.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Maxim Group assumed coverage on Polaryx Therapeutics in a research note on Friday, February 27th. They issued a "buy" rating and a $10.00 price objective on the stock. Weiss Ratings started coverage on shares of Polaryx Therapeutics in a report on Friday, April 24th. They set a "sell (e-)" rating on the stock. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $10.00.

Polaryx Therapeutics Stock Down 16.3%

The stock has a fifty day simple moving average of $5.28.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.